Title of Invention	"PHARMACEUTICAL COMPOSITIONS COMPRISING POLYETHYLENE GLYCOL HAVING A MOLECULAR WEIGHT OF LESS THAN 600 DALTONS"
Abstract	A liquid pharmaceutical composition comprising a biodegradable polymer, polyethylene glycol having a molecular weight of less than 600 Daltons, a pharmaceulically active agent and less than 0.5 % nf an biologically acceptable organic solvent.

Full Text

PHARMACEUTICAL COMPOSITIONS COMPRISING POLYETHYLENE 6LYCOL HAVING A MOLECULAR WEIGHT OF LESS THAN 600 DALTONS The present invention relates to liquid pharmaceutical compositions, in particular to depot formulations comprising a pharmaceutically active agent and to a process for preparing said depot formulations. Depot formulations are typically administered parenterally. The active agent in liquid form may be administered by injection subcutaneously or intramuscularly through a small gauge needle or placed into accessible tissue sites through a cannula. However parenteral administration may be very painful especially if repeated injections are necessary. Furthermore, there may be difficulties with depot formulations which are administered in liquid form comprising more than 50 % of an organic solvent and which form a solid implant in the body after injection. Often the solidifying process starts in the syringe before Injection and causes needle clogging. Depot formulations which form implants after injection may comprise a polymer or a mixture of polymers. These polymers have to be dissolved in an organic solvent. If the organic solvent remains in the solution forlnjection it might cause severe tissue irritation or necrosis at the site of implantation. A variety of approaches have been developed to provide processes for preparing depot formulations. However these processes are often very complex comprising many different steps. Several processes include a heating step which might cause severe stability problems, e.g. of the excipients of the depot formulation such as polymers. There is a need to provide improved depot formulations and simplified processes to prepare said depot formulations to overcome the above mentioned difficulties. Surprisingly it has been found that advantageous parenteral depot formulations with a biodegradable polymer may be obtained if the composition comprises polyethylene glycol (PEG) with a molecular weight of less than 600 Daltons and less than about 0.5% of any other organic solvent. The present invention provides in one aspect a liquid composition comprising" (a) a biodegradable polymer, (b) a polyethylene glycol having a molecular weight of less than 600 Daltons, (c) a pharmaceutically active agent, and (d) less than about 0.5% of a pharmaceutically acceptable solvent, and optionally (e) an additive The composition of the invention may be stored e.g. in prefillcd syringe over an extended period of time without precipitation. Further, the compositions of the invention are well tolerated, e.g. may show only negligible irritating, necrotic or toxic effects. The depot formulations of the present invention are adapted to release all or substantially all the active agent over an extended period of time. In another'aspect the invention provides a process for preparing a depot formulation comprising the steps: (i) dissolving a biodegradable polymer in a pharmaceutically acceptable organic solvent (ii) optionally adding an additive to the polymer/solvent solution of step (i) (iii) dissolving a pharmaceutically active agent in polyethylene glycol with a molecular weight of less than 600 Daltons (iv) mixing solution (i) and (iii) or (ii) and (iii) (v) removing the pharmaceutically acceptable organic solvent from the mixture e.g. by stirring and N2 urging under reduced pressure or by tangential cross-flow filtration to afford dia-filtration. In a further aspect the invention provides a process for preparing a depot formulation comprising the steps: (i) dissolving a biodegradable polymer in a pharmaceutically acceptable organic solvent (ii) optionally mixing an additive with polyethylene glycol with a molecular weight of less than 600 Daltons. (ill) dissolving a pharmaceutically active agent in polyethylene glycol with a molecular weight of less than 600 Daltons or in the polyethylene glycol/additive mixture of step (ii) (iv) mixing solution (i) and (iii) (v) removing the pharmaceuticaily acceptable organic solvent from the mixture e.g by stirring and N2 urging under reduced pressure or by tangential cross-flow filtration to afford dia-filtration. According to the invention, a pharmaceutically acceptable, organic solvent is used to dissolve the biodegradable polymer but this solvent is removed at the end of the process. The resulting compositions of the invention contain only minor amounts of organic solvent, e.g. irritating solvent, e.g. less than 0.5 % by weight based on the total weight of the composition. The polymer of the composition of the invention may be a synthetic or a natural polymer. The polymer may be either a biodegradable or non-biodegradable or a combination of biodegradable and non-biodegradable polymers, preferably a biodegradable polymer may be used. By "polymer" is meant a homopolymer or a copolymer. As used herein, "biodegradable" means a material that should degrade by bodily processes to products readily disposable by the body and should not accumulate in the body. Suitable polymers include (a) linear or branched polyesters which are linear chains radiating from a polyol moiety, e.g. glucose, (b) polyesters such as D-, U- or racemic polylactic acid, polyglycolic acid, polyhydroxy- butyric acid, polycaprolactone, polyalkylene oxalate, polyalkylene glycol esters of acids of the Kreb's cycle, e.g. citric acid cycle, and the like and combinations thereofT (c) polymers of organic ethers, anhydrides, amides, and orthoesters, (d) copolymers of organic esters, ethers, anhydrides, amides, and ortho&sters by themselves or in combination with other monomers. The polymers may be cross-linked or non-cross-linked. Usually not more than 5%, typically less than 1% are cross-linked. The preferred polymers of this invention are linear polyesters, and branched chain polyesters. The linear polyesters may be prepared from the a-hydroxy carboxylic acids, e.g. lactic acid and glycolic acid, by condensation of the lactone dimers, see e.g. US 3,773,919, the contents of which are incorporated herein by reference. The preferred polyester chains in the linear or branched (star) polymers are copolymers of the a-carboxylic acid moieties, lactic acid and glycolic acid, or of the lactone dimers. The molar ratios of lactide: glycolide of polylactide-co-glycolides preferably used according to the invention is preferably from about 95:5 to 5:95, e.g. 75:25 to 25:75, e.g. 60:40 to 40:60, with from 55:45 to 45:55, e.g. 52:48 to 48:52, e.g. 50:50. Linear polyesters, e.g. linear polylactide-co-glycolides (PLG), preferably used according to the invention have a weight average molecular weight (Mw) between about 1,000 and about 50,000 Da, e.g. about 10,000 Da, and a polydispersity M*/Mn e.g. between 1.2 and 2. The intrinsic viscosities of linear polymers of Mw 1000 to 50,000 are 0.05 to 0.6 dl/g, in chloroform. Suitable examples include e.g. those commonly known and commercially available as Resomers® from Boehringer Ingelheim, in particular Resomers® RG, e.g. Resomer® RG 502, 502H, 503, 503H, 504, 504H. Branched polyesters, e.g. branched polylactide-co-glycolides, preferably used according to the invention may be prepared using polyhydroxy compounds e.g. polyol e.g. glucose or mannitol as the initiator. These esters of a polyol are known and "described e.g. in GB 2,145,422 B, the contents of which are incorporated herein by reference. The polyol contains at least 3 hydroxy groups and has a molecular weight of up to 20,000 Da, with at least 1, preferably at least 2, e.g. as a mean 3 of the hydroxy groups of the polyol being in the form of ester groups, which contain poly-lactide or co-poly-lactide chains. Typically 0.2% glucose is used to initiate polymerization. The branched polyesters (Glu-PLG) have a central glucose moiety having rays of linear polylactide chains, e.g. they have a star shaped structure. The branched polyesters having a central glucose moiety having rays of linear polylactide-co-glycolide chains (Glu-PLG) may be prepared by reacting a polyol with a lactide and preferably also a glycolide at an elevated temperature in the presence of a" catalyst, which makes a ring opening polymerization feasible. The branched polyesters having a central glucose moiety having rays of linear polylactide-co-glycolide chains (Glu-PLG) preferably have a weight average molecular weight M* in the range of from about 1,000 to 55,000, preferably 20,000, e.g. 10,000 Da, and a polydispersity e.g. of from 1.1 to 3.0, e.g. 2.0 to 2.5. The intrinsic viscosities of star polymers of M* 10,000 to Mw 50,000 are 0.05 to 0.6 dl/g in chloroform. A star polymer having a Mw of 50,000 has a viscosity of 0.5 dl/g in chloroform. The desired rate of degradation of polymers and the desired release profile for compounds of the invention may be varied depending on the kind of monomer, whether a homo- or a copolymer or whether a mixture of polymers is employed. A mixture of polymers may comprise at least two different kinds of polymers, e.g. as listed under (a) to (e) above, or two polymers of the same polymer class with different properties. For example, a mixture of polymers may comprise a polymer having a medium weight average molecular weight, e.g. from about 30,000 to about 50,000 Da, e.g. of about 20,000 Da, and of a polymer having a low weight average molecular weight, e.g. of about 2.000 to about 20,000 Da, e.g. of about 10,000 Da. Preferably, the pblymer matrix comprises a linear and/or branched polylactide-co-glycolide. More preferably, the polymer matrix comprises a Resomer® RG and/or a star polylactide-co-glycolide polymer having a weight average molecular weight of about 10,000 Da and/or a star polylactide-co-glycolide polymer having a weight average molecular weight of about 50,000 Da. The ratio of linear to branched polylactide-co-glycolide preferably is 0 : 100 to 100:0, e.g. 50: 50 to 25: 75. The solvent of the present invention may be miscible with polyethylene glycol. Examples of such solvents include N-methyl-2-pyrrolidone, 2-pyrrolidone, ethanol, acetone, acetonitrile, methyl acetate, methylene chloride, ethyl acetate, methyl ethyl ketone, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, caprolactam, decylmethylsulfoxide, oleic acid, and 1-dodecylazacycloheptan-2-one. Preferably acetone or methylene chloride may be used. The amount of polymer dissolved in e.g. acetone or methylene chloride may be from about 10% w/v to about 40% w/v, preferably from about 15% w/v to about 30% w/v. Optionally a an additive may be added to the polymer/solvent solution and/or~to the polyethylene glycol/drug substance solution. The additive may improve the solubility of the polymer and the drug substance of the active ingredient. The co-solvent may further modulate the drug release in vitro or in vivo. The additive may be present in a amount of from about 0.1% to about 20% w/v, preferably from about 1% to about 5%. Examples of such additives include methanol, ethanol, propylene glycol, liquid surfactant such as poly(oxyethylene) sorbitan esters (Tweens) or glycerin polyoxyethyiene ester of castor oil (Cremophor EL), lactic acid, acetic acid, glycerol, N,N dimethylacetamide, benzyl benzoate, polyoxyethylated fatty acid, lecithin, soybean oil, seaflower oil, vegetable oils, cotton sead oils, oligormers of poly(l-lactide) of poly(d,l lactide) of poly(lactide co-glycolide) or a mixture of these oligomers. The pharmaceutically active agent may be dissolved or dispersed in liquid polyethylene glycols (PEG), e.g. PEG 200, PEG 300, PEG 400, PEG 540 or PEG 600 (Handbook of Pharmaceutical Excipients loc.cit., p. 454) or PEG with modified end groups e.g. polyethylene glycol mono and di-alkyl ether (Handbook of Pharmaceutical Excipients loc.cit. p. 469) or polyethylenglycol 600 mono and di-acid at room temperature, e.g. 25° C, e.g. depending on its solubility in this solvent with or without a co-solvent. Details of suitable excipients for use in the process of the invention are described in the "Handbook of Pharmaceutical Excipients", Rowe, Sheskey and Weller, 4th Edition 2003 which is incorporated by reference. For the purpose of the invention "pharmaceutically active agent" means all substances that produce a pharmaceutical or a therapeutic effect. Examples of pharmaceutically active agents include but are not limited to peptides, polypeptides, proteins, carbohydrates, oligonucleotides, RNA and DNA. A few examples of peptides are antibodies, growth hormones, e.g. epidermal growth factor (EGF), prolactin, luiiberin or luteinizing hormone releaseing hormone (LH-RH), glucagon, gastrin, pentagastrin, urogastron, secretin, enkephalins, endorphins, angiotensins, renin, bradykinin, bacitracins, polymyxins, colistins, tyrocidin, gramicidines, insulin, octreotide, e.g. as disclosed in US 4,395,403, interferons, erythropoietin, calcitonin, heparin, sornatostatin analogues, e.g. somatostatin pamoate or di-aspartate, cell stimulating factors and parathyroid hormones. A preferred active agent may be a somatostatin analogue which is dissolved tn polyethylene glycol. A more preferred active agent may be somatostatin pamoate or di-aspartate which may be dissolved 1:1 in polyethylene glycol to form a solution with up to 20 mg/ml of the active agent. Somatostatin is a tetradecapeptide having the structure H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Somatostatin analogues of particular interest have been described e.g. in WO 97/01579 and WO 97/25977. Said somatostatin analogues comprise the amino acid sequence of formula I -(D/L)Trp-Lys-Xi -X2 - ' I wherein Xt is a radical of formula (a) or (b) —NH—r—CO— —NH—|— CO— -O-CH,^ (a) - CH2 (b) CH? R2 wherein RI is optionally substituted phenyl, wherein the substituent may be halogen, methyl, ethyl, methoxy or ethoxy, R2 is -Zr-CHz-Ri. -CHrCO-O-CH2-Ri, wherein 2\ is O or S, and residue Lys of said sequence corresponding to the residue Lys9 of the native somato- X2 is an cx-amino acid having an aromatic residue on the C0 side chain, or an amino acid unit selected from Dab, Dpr, Dpm, His,(Bzl)HyPro, thienyl-Ala, cyclohexyl-Ala and t-butyl-Ala, the residue L; statin-14. By somatostatin analogue as used herein is meant a straight-chain or cyclic peptide derived from that of the naturally occurring somatostatin-14, comprising the sequence of formula I and wherein additionally one or more amino acid units have been omitted and/or replaced by one or more other amlno acid radical(s) and/or wherein one or more functional groups have been replaced by one or more other functional groups and/or one or more groups have been replaced by one or several other isosteric groups. In general the term covers all modified derivatives of the native somatostatin-14 comprising the above sequence of formula I which have binding affinity in the nM range to at least one somatostatin receptor subtype as defined hereinafter. Preferably, the somatostatin analogue is a compound in which the residues at positions 8 through 11 of the somatostatin-14 are represented by the sequence of formula I as defined above.More preferably, the somatostatin analogue is a compound as disclosed above comprising a hexapeptide unit, the residues at positions. 3 through 6 of said hexapeptide unit comprising the sequence of formula I. Particularly preferred is a somatostatin hexapeptide wherein the residues at positions 1 and 2 of the hexapeptide unit may be any of those as known in the art, e.g. as disclosed by A.S. Dutta in Small Peptides, Vol.19, 292-354, Elsevier, 1993, or as substituents for, Phe8 and/or Phe7 of somatostatin-14. More particularly the somatostatin analogue is a compound in which the hexapeptide unit is cyclic, e.g. having a direct peptide linkage between the a-carbonyl group of the residue at position 6 and the a-amino group of the residue at position 1. While Lys, Xi and X2 in the sequence of formula I have the L-configuration, Trp may have the D- or L-configuration. Preferably Trp has the D-configuration. Xi is preferably a residue of formula (a) or (b), R2 being preferably -ZrCIVRi or When X2 comprises an aromatic residue on the Caside chain, it may suitably be a natural or unnatural a-amino acid, e.g. Phe, Tyr, Trp, Nal, Pal, benzothienyl-Ala, Tic and thyronin, preferably Phe or Nal, more preferably Phe. X2 is preferably an a-amino acid bearing an aromatic residue on the C0 side chain. When RI is substituted phenyl, it may suitably be substituted by halogen, methyl, ethyl, methoxy or ethoxy e.g. in ortho and/or para. More preferably RI is unsubstituted phenyl. Zi is preferably O. Representative compounds of the invention are e.g. compounds of formula (II) cyclo[A - ZZ - (D/L)Trp - Lys - X - X ] (II) 3 12 12 3456 wherein X1 and X2 are as defined above, A is a divalent residue selected from Pro, (R3-NH-CO-O)Pro-, R5-N-R7-Pro-, HO-R7-Pro-, R- wherein R3 is NRsRg-C^alkylene, guanidino-C^alkylene or C^alkylene-COOH, R& is H, C^alkyl or has independently one of the significances given for RS, Rabis H or Chalky!, R, is OH or NR5R6, Rb is -(CH2)i-3- or -CH(CH3)-, R ZZa is a natural or unnatural cc-amino acid unit. ZZa may have the D- or L-configuration. When ZZa is a natural or unnatural a-amino acid unit, it may suitably be e.g. Thr, Ser, Ala, Val, lie, Leu, Nle, His, Arg, Lys, Nal, Pal, Tyr, Tip, optionally ring-substituted Phe or N°-benzyl-Gly. When ZZa is Phe, the benzene ring thereof may be substituted by e.g. NH2l NO2, CH3l OCH3 or halogen, preferably in para position. When ZZa is Phe, the benzene ring thereof is preferably unsubstituted. When A comprises a Pro amino acid residue, any substituent present on the proline ring, e.g. R3-NH-CO-0- etc., is preferably in position 4. Such substituted proline residue may exist in the cis form, e.g. as well as in the trans form. Each geometric isomer individually as well as mixtures thereof are compounds of the invention. When A is (NR8R9-CMalkylene-NH-CO-O)Pro- where NR8R9 forms a heterocyclic group, such group may be aromatic or saturated and may comprise one nitrogen or one nitrogen and a second heteroatom selected from nitrogen and oxygen. Preferably the heterocyclic group is e.g. pyridyl or morpholino. C2.eAIkylene "n this residue is preferably -CHrCH2-. Any acy! as R5, Re, Re and Rg in A may be e.g. R12CO- wherein Ri2 is H, CMalkyl, C2^alkenyl, C^cycloalkyl or benzyl, preferably methyl or ethyl. When R-ia or RH in A is ring-substituted benzyl, the benzene ring may be substituted as indicated above for ZZa. Particularly preferred are compounds of formula III (Figure Remove) wherein the configuration at C-2 is (R) or (S) or a mixture thereof, and wherein R is NRi0Rn-CMalkylene or guanidine-C^alkylene, and each of RIO and RU independently is H or Chalky), in free form, in salt form or protected form. Preferably R is NR10Rn-CMalkylene. Preferred compounds of formula II are the compounds wherein R is 2-amino-ethyl, namely cyclo[{4-(NH2-C2H4-NH-CO-O-)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] (referred herein to as Compound A) and cyclo[{4-(NH2-C2H4-NH-CO- 0-)Pro}-DPhg-DTrp-Lys-Tyr(4-Bzl)-Phe], in free form, salt form or protected form. Phg means -HN-CH(CBH5}-CO- and Bzl means benzyl. A compound of the invention in protected form corresponds to a somatostatin analogue wherein at least one of the amino groups is protected and which by deprotection leads to a compound of formula II, preferably physiologically removable. Suitable amino protecting groups are e.g. as disclosed in "Protective Groups in Organic Synthesis", T. W. Greene, J. Wiley & Sons NY (1981), 219-287, the contents of Which being incorporated herein by reference. Example of such an amino protecting group is acetyl. A compound of the invention may exist e.g. in free or salt form. Salts include acid addition salts with e.g. inorganic acids, polymeric acids or organic acids, for example with hydrochloric acid, acetic acid, lactic acid, aspartic acid, benzoic acid, succinic acid or pamoic acid. Acid addition salts may exist as mono- or divalent salts, e.g. depending whether 1 or 2 acid equivalents are added. Preferred salts are the lactate,' aspartate, benzoate, succinate and pamoate including mono- and di-salts, more preferably the aspartate di-salt and the pamoate monosalt. In another aspect the invention provides a pharmaceutical composition comprising a somatostatin analogue, e.g. somatostatin pamoate, obtainable by the process of the invention. The composition may further comprise a polymer and polyethylene glycol as described above. In a further aspect of the invention the composition obtainable by the process of the present invention may be in liquid form, e.g. a solution. After sterile filtration through a 0.2 micrometer filter the liquid composition, e.g. solution, may be placed in a syringe. Sterilization may also be achieved by terminal sterilization with gamma irradiation at 20 to 30 kGy preferably at 25 kGy under cooled conditions, e.g. 2 to 8 °C or -70 °C. The sterilized solution may be injected through a needle, e.g. an up to 20 G needle, into the body subcutaneously or intramuscularly. Once in place the solvent, e.g. polyethylene glycol will dissipate and the polymer together with the pharmaceuticatly active agent solidifies to form the implant. Accordingly to the Invention, preferably a prefilled syringe may be provided together with instructions for use. In another aspect the invention provides a depot formulation for extended release of the pharmaceutically active agent. The implant formed after injection into the body may release the active agent over an extended period of time. The desired release profile'may depend on the kind of monomer, whether a homo- or a co-polymer or whether a mixture of polymers is employed. The release period may range from 1 up to 12 weeks, e.g. 1 to 8 weeks. The compositions of the invention are useful for treatment of the known indications of the particular active agent incorporated in the polymer. Compositions of the invention comprising a somatostatin anologue may be useful in the following indications: a) for the prevention or treatment of disorders with an aetiology comprising or associated with excess GH-secretion and/or excess of IGF-1 e.g. in the treatment of acromegaly as well as in the treatment of type I or type II diabetes mellitus, especially complications thereof, e.g. angiopathy, diabetic proliferative retinopathy, diabetic macular edema, nephropathy, neuropathy and dawn phenomenon, and other metabolic disorders related to insulin or glucagon release, e.g. obesity, e.g. morbid obesity or hypothalamic or hyperinsulinemic obesity, ' b) in the treatment of enterocutaneous and pancreaticocutaneous fistula, irritable bowel syndrom, inflammatory diseases, e.g. Grave's Disease, inflammatory bowel disease, psoriasis or rheumatoid arthritis, polycystic kidney disease, dumping syndrom, watery diarrhea syndrom, AIDS-related diarrhea, chemotherapy-induced diarrhea, acute or chronic pancreatitis and gastrointestinal hormone secreting tumors (e.g. GEP tumors, for example vipomas, glucagonomas, insulinomas, carcinoids and the like), lymphocyte malignancies, e.g. lymphomas or leukemias, hepatocellular carcinoma as well as gastrointestinal bleeding, e.g variceal oesophagial bleeding, c) for the prevention or treatment of angiogenesis, inflammatory disorders as indicated above including inflammatory eye diseases, macular edema, e.g. cystoid macular edema, idiopathic cystoid macular edema, exudative age-related macular degeneration, choroidal neovascularization related disorders and proliferative retinopathy, d) for preventing or combating graft vessel diseases, e.g. allo- or xenotransplant vasculo- pathies, e.g. graft vessel atherosclerosis, e.g. in a transplant of organ, e.g. heart, lung, combined heart-lung, liver, kidney or pancreatic transplants, or for preventing or treating vein graft stenosis, restenosis and/or vascular occlusion following vascular injury, e.g. caused by catherization procedures or vascular scraping procedures such as percutaneous transluminal angioplasty, laser treatment or other Invasive procedures which disrupt the integrity of the vascular intima or endothelium, e) for treating somatostatin receptor expressing or accumulating tumors such as pituitary tumors, e.g. Cushing's Disease, gastro-enteropancreatic, carcinoids, central nervous system, breast, prostatic (including advanced hormone-refractory prostate cancer), ovarian or colonic tumors, small cell lung cancer, malignant bowel obstruction, paragangliomas, kidney cancer, skin cancer, neuroblastomas, pheochromocytomas, medullary thyroid carcinomas, myelomas, lymphomas, Hodgkins and non-Hodgkins lymphomas, bone tumours and metastases thereof, as well as autoimmune or inflammatory disorders, e.g. rheumatoid arthritis, Graves disease or other inflammatory eye diseases. Preferably, the compositions of the invention are useful in the treatment of acromegaly and cancer, e.g. Cushing's Disease. The activity and the characteristics of the liquid compositions of the invention may be indicated in standard clinical or animal tests. Appropriate dosage of the composition of the invention will of course vary, e.g. depending on the condition to be treated (for example the disease type of the nature of resistance), the drug used, the effect desired and the mode of administration. For compositions of the invention comprising a somatostatin analogue satisfactory results are obtained on administration, e.g. parenteral administration, at dosages on the order of from about 0.2 to about 60 mg, preferably from about 5 to about 40 mg per injection per month or about 0.03 to about 1.2 mg per kg animal body weight per month, administered once or in divided doses. Suitable monthly dosages for patients are thus in the order of about 0.3 mg to about 40 mg of a somatostatin analogue, e.g. Compound A pamoate. The composition may be administered every 2 to 3 months. Suitable dosages for every 3 months administration are about 1 mg to about 180 mg. Following is a description by way of example only of processes and compositions of the invention. Example 1 The solubility of different polymers (linear polymer): in polyethylene glycol is tested. The solubility of the linear polymers (Resomer®) and the star polymer (Poly(D).L-lactide-co-glycolide), D,L PLG-Glu is shown in table 1. Table 1 (Table Remove) Example 2 Preparation of 20 ml polymer/PEG solution: 4.004 g Resomer RG 502 H are dissolved in 13.3 ml acetone. 20 ml polyethylene glycol PEG is added to this solution together with 25 mg/ml of Compound A pamoate. The complete solution is stirred 4 hours at room temperature and N2 urging under reduced pressure. After sterile filtration the solution is filled in a syringe. The obtained prefilled syringe may be used for subcutaneous administration. Example 3 4 g of resomer RG502H were dissolved in 6.6 ml methylene chloride. 0.250 g Compound A di-aspartate were dissolved in 2 ml water and added to 20 ml PEG300. Both polymer and drug substance solutions were mixed together. The methylene chloride was evaporated for 5 hours at 40 "C in a water batch resulting in a injectable in situ forming depot formulation of 1.25 % w/v Compound A di-aspartate and 20% w/v Resomer RG502H in PEG 300. Example 4 1.5 g of resomer RG502H and 1.0 g of oligomers of poly(lactide-co-glycolide) 50:50 were dissolved in 3.3 ml methylene chloride. 0.250 g Compound A-pamoate were dissolved in 10 ml PEG300. Both polymer and drug substance solutions were mixed together. The methylene chloride was evaporated for 5 hours at 40 °C in a water batch resulting in a Injectable in situ forming depot formulation of 2.5 % w/v Compound A pamoate and 15% w/v Resomer RG502H and 10% oligomers in PEG 300. Examples 1.54 g of resomer RG502H and 0.5 g of benzyl benzoate were dissolved in 3.3 ml methylene chloride. 0.250 g Compound A-pamoate were dissolved in 10 ml PEG300. Both polymer and drug substance solutions were mixed together. The methylene chloride was evaporated for 5 hours at 40 °C in a water batch resulting in a injectable in situ forming depot formulation of 2.5 % w/v Compound A pamoate and 15% w/v Resomer RG502H and 5% benzyl benzoate in PEG 300. Example 6: 2.0 g of resomer RG502H were dissolved in 3.3 ml methylene chloride. 0.250 g Compound A-pamoate were dissolved in 10 ml PEG250 diethylether. Both polymer and drug substance solutions were mixed together. The methylene chloride was evaporated for 5 hours at 40 °C in a water batch resulting in a injectable in situ forming depot formulation of 2.5 % w/v Compound A pamoate and 20% w/v Resomer RG502H in PEG 250 diethylether. Example 7 4 g of resomer RG502H were dissolved in 6.6 ml methylene chloride. 0.50 g Compound A pamoate were dissolved in 20 ml PEG300. Both polymer and drug substance solutions were mixed together. The methylene chloride was evaporated for 5 hours at 40 °C in a water batch resulting in a injectable in situ forming depot formulation of 2.5 % w/v Compound A pamoate and 20% w/v Resomer RG502H in PEG 300. We Claim 1. A liquid pharmaceutical composition comprising (a) a linear or branched polylactide-co-glycolide as biodegradable polymer (b) a polyethylene glycol having a molecular weight of less than 600 Daltons (c) cyclo[{4-(NH2-C2H4-NH-CO-O-)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] pamoate or di-aspartate as pharmaceutically active agent, and (d) less than about 0.5% of a pharmaceutically acceptable organic solvent, and optionally (e) an additive 2. The liquid pharmaceutical composition as claimed in claim 1 wherein the polyethylene glycol is PEG 200, PEG 300, PEG 400 or PEG 600 or di-alkyl ether PEG. 3. The liquid pharmaceutical composition as claimed in claim 1 or 2 wherein the pharmaceutically acceptable organic solvent is chosen from N-methyl-2-pyrrolidone, 2-pyrrolidone, ethanol, acetone, acetonitrile, methyl acetate, ethyl acetate, methyl ethyl ketone, methylene chloride, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, caprolactam, decylmehylsulfoxide, oleic acid, and l-dodecylazacycloheptan-2-one. 4. The liquid pharmaceutical composition as claimed in any preceding claim wherein the additive is choosen from methanol, ethanol, propylene glycol , liquid surfactant such as poly(oxyethylene) sorbitan esters or glycerin polyoxyethylene ester of ricin oil, lactic acid, acetic acid, glycerol, N,N dimethylacetamide, benzyl benzoate, polyoxyethylated fatty acid, lecithin, soybean oil , seaflower oil, vegetable oils, cotton sead oils, oligormers of poly(l-lactide) of poly(d,l lactide) of poly(lactide co-glycolide) or a mixture of these oligomers. 5. A process for preparing a depot formulation comprising the steps: i) dissolving a linear or branched polylactide-co-glycolide as biodegradable polymer in a pharmaceutically acceptable organic solvent ii) optionally adding an additive to the polymer/solvent solution of i) iii) dissolving cyclo[{4-(NH2-C2H4-NH-CO-O-)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] pamoate or di-aspartate as pharmaceutically active agent in polyethylene glycol having a molecular weight of less than 600 Daltons iv) mixing solution (i) and (iii) or (ii) and (iii) v) removing the pharmaceutically acceptable organic solvent from the mixture. 6. The process as claimed in claim 5 wherein optionally an additive is added to the polyethylene glycol before dissolving the pharmaceutically active agent in this solution. 7. The process as claimed in claim 5 wherein at least two different polymers are dissolved in a pharmaceutically acceptable organic solvent. 8. The process as claimed in any one of claims 5 to 7 wherein the polyethylene glycol is PEG 200, PEG 300, PEG 400 or PEG 600 or di-alkyl ether PEG. 9. The process as claimed in any one of claims 5 to 8 wherein the pharmaceutically acceptable organic solvent is chosen from N-methyl-2-pyrrolidone, 2-pyrrolidone, ethanol, acetone, acetonitrile, methyl acetate, ethyl acetate, methyl ethyl ketone, methylen chloride, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, caprolactam, decylmehylsulfoxide, oleic acid, and l-dodecylazacycloheptan-2-one.

Documents:

7045-delnp-2006-abstract.pdf

7045-delnp-2006-Claims-(14-06-2013).pdf

7045-delnp-2006-Claims-(22-11-2012).pdf

7045-delnp-2006-claims.pdf

7045-delnp-2006-Correspondence Others-(04-06-2012).pdf

7045-delnp-2006-Correspondence Others-(06-06-2012).pdf

7045-delnp-2006-Correspondence Others-(14-06-2013).pdf

7045-delnp-2006-Correspondence Others-(22-11-2012).pdf

7045-delnp-2006-Correspondence-others (04-06-2008).pdf

7045-delnp-2006-correspondence-others.pdf

7045-delnp-2006-description (complete).pdf

7045-delnp-2006-form-1.pdf

7045-delnp-2006-Form-18 (04-06-2008).pdf

7045-delnp-2006-form-2.pdf

7045-delnp-2006-Form-3-(04-06-2012).pdf

7045-delnp-2006-Form-3-(22-11-2012).pdf

7045-DELNP-2006-Form-3.pdf

7045-delnp-2006-form-5.pdf

7045-delnp-2006-GPA-(22-11-2012).pdf

7045-delnp-2006-pct-304.pdf

7045-delnp-2006-pct-search report.pdf